

10/561,949

ring bonds :

1-2 1-6 1-7 2-3 3-4 4-5 5-6 7-8 8-9 9-18 18-20

exact/norm bonds :

1-7 7-8 8-9 9-18 10-11 15-16 15-17 18-19 18-20

exact bonds :

8-10 10-12 12-13 13-14 13-15

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

G1:C,O,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS

11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS


19:CLASS 20:CLASS

L10 STRUCTURE UPLOADED

=> dis

L10 HAS NO ANSWERS

L10 STR



G1 C,O,N

Structure attributes must be viewed using STN Express query preparation.

=> s L10 full

10/561,949

FULL SEARCH INITIATED 13:17:42 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 4078 TO ITERATE

100.0% PROCESSED 4078 ITERATIONS 15 ANSWERS
SEARCH TIME: 00.00.01

L11 15 SEA SSS FUL L10

=> fil hcap uspatful		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	863.20	863.41

FILE 'HCAPLUS' ENTERED AT 13:17:56 ON 02 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 13:17:56 ON 02 MAY 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


=> L11
L12 3 L11

=> d L12 1-3 ibib abs hitstr

L12 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 ACCESSION NUMBER: 2006:710798 HCAPLUS
 DOCUMENT NUMBER: 145:167297
 TITLE: Preparation of macrocyclic lactones for treatment of β -amyloid related disease
 INVENTOR(S): Betschart, Claudia; Lerchner, Andreas; Machauer, Rainer; Rueger, Heinrich; Tintelnot-Blomley, Marina; Veenstra, Siem Jacob
 PATENT ASSIGNEE(S): Novartis AG, Switz.; Novartis Pharma GmbH
 SOURCE: PCT Int. Appl., 142 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006074950	A1	20060720	WO 2006-EP280	20060113
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RN: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM PRIORITY APPLN. INFO.: GB 2005-682 A 20050113 GB 2005-20165 A 20051004				

OTHER SOURCE(S): MARPAT 145:167297
 GI




AB Title compds. [I: R1 = CHRECONRaRb, (CH2)kNRcRd; k = 0-2; Ra, Rb = H, (substituted) alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl; Rc, Rd = H, (substituted) alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, chroman-4-yl, isochroman-4-yl, 1,3,4,5-tetrahydrobenzo[c]oxepin-5-yl, etc.; RaRbN, RcRdN
 = (substituted) pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl; Re =

L12 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 900797-97-9 HCAPLUS
 CN 3,16,18-Triazatricyclo[15.3.1.16,10]docosa-1(21),6,8,10(22),16,19-hexaene-4-butanamide, N-butyl- γ -hydroxy-19-methoxy- α -methyl-2-oxo-, (α R, γ S,4S) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 900797-98-0 HCAPLUS
 CN 3,16,18-Triazatricyclo[15.3.1.16,10]docosa-1(21),6,8,10(22),16,19-hexaene-4-butanamide, N-butyl- γ -hydroxy- α ,19-dimethyl-2-oxo-, (α R, γ S,4S) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (substituted) alkyl, cycloalkyl, etc.; R2 = H, alkyl; R3 = H, alkyl, (substituted) AO2CNH, etc.; A = alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, etc.; Ar = (substituted) (hetero)aryl; U = bond, O, CF2, CHF, cyclopropylene, etc.; V1 = H, V2 = OH; V1V2 = O; X = (substituted) alkylene, cycloalkylene, piperidinylene, pyrrolidinylene, etc.; X1 = C(Rf)2; Rf = H, F, (substituted) alkyl, alkoxyalkyl, etc.; Y = bond, O, SO2, etc.; Z = O, CH2, CF2, CHF, cyclopropylene, bond; ring contains
 14-17 atoms, were prepd. Thus, (S)-4-[(R)-1-hydroxy-2-(3-isopropylbenzylamino)ethyl]-18-methyl-3,15,17-triazatricyclo[14.3.1.1*6,10*]heneicosa-1(19),6,8,10(21),16(20),17-hexaen-2-one [prepn. from [(1S,2R)-1-(3-allylbenzyl)-3-[benzyloxycarbonyl-(3-isopropylbenzyl)amino]-2-hydroxypropyl]carbamate tert-Bu ester and 2-allylamino-6-methylisonicotinic acid hydrochloride outlined] inhibited cellular release of amyloid peptide 1-40 with IC50 = 0.04 nM.
 IT 900797-95-7P 900797-96-8P 900797-97-9P
 900797-98-0P 900797-99-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of macrocyclic lactones for treatment of β -amyloid related disease)

RN 900797-95-7 HCAPLUS
 CN 11-Oxa-3,16,18-triazatricyclo[15.3.1.16,10]docosa-1(21),6,8,10(22),16,19-hexaene-4-butanamide, N-butyl- γ -hydroxy-19-methoxy- α -methyl-2-oxo-, (α R, γ S,4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 900797-96-8 HCAPLUS
 CN 3,15,17-Triazatricyclo[14.3.1.16,10]heneicosa-1(20),6,8,10(21),15,18-hexaene-4-butanamide, N-butyl- γ -hydroxy-18-methoxy- α -methyl-2-oxo-, (α R, γ S,4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L12 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 900797-99-1 HCAPLUS
 CN 3,15,17-Triazatricyclo[14.3.1.16,10]heneicosa-1(20),6,8,10(21),15,18-hexaene-4-butanamide, N-butyl- γ -hydroxy- α ,18-dimethyl-2-oxo-, (α R, γ S,4S) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 900798-76-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of macrocyclic lactones for treatment of β -amyloid related disease)

RN 900798-76-7 HCAPLUS
 CN 3,15,17-Triazatricyclo[14.3.1.16,10]heneicosa-1(20),6,8,10(21),12,15,18-heptaene-4-butanamide, N-butyl- γ -hydroxy- α ,18-dimethyl-2-oxo-, (α R, γ S,4S) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.

L12 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE


FORMAT

L12 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:29320 HCAPLUS
DOCUMENT NUMBER: 142:134632
TITLE: Macrocyclic compounds having aspartic protease inhibiting activity and pharmaceutical uses thereof
INVENTOR(S): Betschart, Claudia; Tintelnot-Blomley, Marina
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SOURCE: ECT Int. Appl., 38 pp.
CODEN: PIXKD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005003106	A1	20050113	WO 2004-EP7247	20040702
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004253667	A1	20050113	AU 2004-253667	20040702
CA 2529571	A1	20050113	CA 2004-2529571	20040702
EP 1654241	A1	20060510	EP 2004-740596	20040702
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1809542	A	20060726	CN 2004-90017405	20040702
BR 2004012286	A	20060919	BR 2004-12286	20040702
US 2006223745	A1	20061005	US 2005-561949	20051222
PRIORITY APPLN. INFO.:			GB 2003-15654	A 20030703
			WO 2004-EP7247	W 20040702

OTHER SOURCE(S): MARPAT 142:134632
GI



AB The preparation of macrocyclic compds., I, (R1 = alkyl, alkoxy, piperidinyl,


L12 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
or pyrrolidinyl; R2, R4 = H, alkyl, cycloalkyl, aryl, heteroaryl etc or R2 and R4, together with the nitrogen to which they are attached, form an optionally substituted piperidino, pyrrolidinyl, morpholino or piperazinyl

group; R3 = H, alkyl; X1 = CH2; X2 = CH2, O, S, CO, COO, OCO, NHCO, CONH, or NR, R being hydrogen or (C1-4)alkyl; Y = (C1-8)alkylen or (C1-8)alkylenoxy(C1-6)alkylen, (C1-8)alkylen or (C1-8)alkylenoxy(C1-6)alkylen; Ar = a Ph ring optionally mono- di- or trisubstituted; Z = CO, A = a natural or unnatural alpha-amino-acid; and n is 0 or 1, or Z = SO2 and AA = an optionally substituted ethylencarbonyl group (derived from a natural or unnatural alpha-amino acid by replacement of the nitrogen by a methylene group), and n is 1) are prep. as aspartic protease inhibitors for the treatment of neurol. and vascular disorders related to beta-amyloid generation and/or aggregation.

IT 824429-16-5P 824429-24-5P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(macrocyclic compds. having aspartic protease inhibiting activity and pharmaceutical uses thereof)

RN 824429-16-5 HCAPLUS
CN 2-Oxa-7-thia-11-azabicyclo[12.3.1]octadeca-1(18),14,16-triene-12-butanamide, N-butyl-γ-hydroxy-α,9-dimethyl-10-oxo-, 7,7-dioxide, (αR,γS,9S,12S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 824429-24-5 HCAPLUS
CN 8-Thia-4-azabicyclo[12.3.1]octadeca-1(18),14,16-triene-3-butanamide, N-butyl-γ-hydroxy-α,6-dimethyl-5-oxo-, 8,8-dioxide, (αR,γS,3S,6S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 824429-11-0P 824429-29-0P 824957-23-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(macrocyclic compds. having aspartic protease inhibiting activity and pharmaceutical uses thereof)
RN 824429-11-0 HCAPLUS
CN 2-Oxa-9,12-diazabicyclo[13.3.1]nonadeca-1(19),15,17-triene-13-butanamide, N-butyl-γ-hydroxy-α,10-dimethyl-8,11-dioxo-, (αR,γS,10S,13S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 824429-29-0 HCAPLUS
CN 8-Thia-4-azabicyclo[13.3.1]nonadeca-1(19),15,17-triene-3-butanamide, N-butyl-γ-hydroxy-α,6-dimethyl-5-oxo-, 8,8-dioxide, (αR,γS,3S,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 824957-23-5 HCAPLUS

CN

2-Oxa-7,10-diazabicyclo[11.3.1]heptadeca-1(17),13,15-triene-11-butanamide, N-butyl-γ-hydroxy-α,8-dimethyl-6,9-dioxo-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 824429-15-4P 824429-21-2P 824429-23-4P

824957-22-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (macrocyclic compds. having aspartic protease inhibiting activity and pharmaceutical uses thereof)


RN 824429-15-4 HCAPLUS

CN

2-Oxa-9-thia-13-azabicyclo[14.3.1]eicosa-1(20),16,18-triene-14-butanamide, N-butyl-γ-hydroxy-α,11-dimethyl-12-oxo-, 9,9-dioxide, (αR,γS,11S,14S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L12 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 824957-22-4 HCAPLUS

CN

2-Oxa-8,11-diazabicyclo[12.3.1]octadeca-1(18),14,16-triene-12-butanamide, N-butyl-γ-hydroxy-α,9-dimethyl-7,10-dioxo-, (9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L12 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 824429-21-2 HCAPLUS

CN

2-Oxa-9-thia-12-azabicyclo[13.3.1]nonadeca-1(19),15,17-triene-13-butanamide, N-butyl-γ-hydroxy-α,10-dimethyl-11-oxo-, 9,9-dioxide, (αR,γS,10S,13S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 824429-23-4 HCAPLUS

CN

2-Oxa-7-thia-11-azabicyclo[12.3.1]octadeca-1(18),14,16-triene-12-butanamide, N-butyl-γ-hydroxy-α-methyl-10-oxo-, 7,7-dioxide, (αR,γS,12S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L12 ANSWER 3 OF 3 USPATFULL on STN

ACCESSION NUMBER:

2006:262229 USPATFULL

TITLE:

Macrocyclic compounds having aspartic protease inhibiting activity and pharmaceutical uses thereof
Betschart, Claudia, Basel, SWITZERLAND
Tintelnot-Blomley, Marina, Maulburg, GERMANY, FEDERAL REPUBLIC OF

INVENTOR(S):

NUMBER	KIND	DATE
US 2006223745	A1	20061005
US 2004-561949	A1	20040702 (10)
WO 2004-EP7247		20040702
		20051222 PCT 371 date

PATENT INFORMATION:

APPLICATION INFO.:

PRIORITY INFORMATION:

GB 2003-15654 20030703

DOCUMENT TYPE:

Utility

FILE SEGMENT:

APPLICATION

LEGAL REPRESENTATIVE:

NOVARTIS, CORPORATE INTELLECTUAL PROPERTY, ONE HEALTH PLAZA 104/3, EAST HANOVER, NJ, 07936-1080, US

NUMBER OF CLAIMS:

12

EXEMPLARY CLAIM:

1

LINE COUNT:

1191

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to macrocyclic compounds of formula (I), wherein R.sub.1 is (C.sub.1-8)alkyl, (C.sub.1-4)alkoxy(C.sub.1-4)alkyl, hydroxy(C.sub.1-6)alkyl, (C.sub.1-4)alkylthio(C.sub.1-4)alkyl, (C.sub.1-6)alkenyl, (C.sub.3-7)cycloalkyl, (C.sub.3-7)cycloalkyl(C.sub.1-4)alkyl, piperidinyl or pyrrolidinyl, R.sub.2 and R.sub.4, independently, are hydrogen or optionally substituted (C.sub.1-8)alkyl, (C.sub.3-7)cycloalkyl, (C.sub.3-7)cycloalkyl(C.sub.1-4)alkyl, aryl, aryl(C.sub.1-4)alkyl, heteroaryl or heteroaryl(C.sub.1-4)alkyl, or R.sub.2 and R.sub.4, together with the nitrogen to which they are attached, form an optionally substituted piperidino, pyrrolidinyl, morpholino or piperazinyl group. R.sub.3 is hydrogen or (C.sub.1-4)alkyl. X.sub.1 is CH.sub.2, X.sub.2 is CH.sub.2, O, S, CO, COO, OCO, HOCO, CONH, or NH, R being hydrogen or (C.sub.1-4)alkyl, Y is (C.sub.1-8)alkyl or (C.sub.1-8)alkylenoxy(C.sub.1-6)alkylen, (C.sub.1-8)alkylen or (C.sub.1-6)alkenylenoxy(C.sub.1-6)alkylen, Ar is a phenyl ring optionally mono- di or trisubstituted by, independently, hydroxy or halogen, whereby X.sub.1, and X.sub.2 are in meta or para position to each other, and either Z is CO, AA is a natural or unnatural

alpha-amino-acid, and n is 0 or 1, or Z is SO.sub.2, AA is an optionally substituted ethylencarbonyl group (derived from a natural or unnatural alpha-amino acid by replacement of the nitrogen by a methylene group), and n is 1; processes for the preparation of these compounds; pharmaceutical compositions and combinations comprising the same; and their use in the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 824429-16-5P 824429-24-5P

(macrocyclic compds. having aspartic protease inhibiting activity and


L12 ANSWER 3 OF 3 USPTAFULL on STN (Continued)

pharmaceutical uses thereof)

RN 824429-16-5 USPTAFULL

CN 2-Oxa-7-thia-11-azabicyclo[12.3.1]octadeca-1(18),14,16-triene-12-butanamide, N-butyl-γ-hydroxy-α,9-dimethyl-10-oxo-, 7,7-dioxide, (αR,γS,9S,12S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 824429-24-5 USPTAFULL

CN 8-Thia-4-azabicyclo[12.3.1]octadeca-1(18),14,16-triene-3-butanamide, N-butyl-γ-hydroxy-α,6-dimethyl-5-oxo-, 8,8-dioxide, (αR,γS,3S,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 824429-11-OP 824429-29-OP 824957-23-5P (macrocyclic compds. having aspartic protease inhibiting activity and pharmaceutical uses thereof)

RN 824429-11-0 USPTAFULL

CN 2-Oxa-9,12-diazabicyclo[13.3.1]nonadeca-1(19),15,17-triene-13-butanamide, N-butyl-γ-hydroxy-α,10-dimethyl-8,11-dioxo-, (αR,γS,10S,13S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 3 OF 3 USPTAFULL on STN (Continued)



IT 824429-15-4P 824429-21-2P 824429-23-4P


824957-22-4P

(macrocyclic compds. having aspartic protease inhibiting activity and pharmaceutical uses thereof)

RN 824429-15-4 USPTAFULL

CN 2-Oxa-9-thia-13-azabicyclo[14.3.1]eicosa-1(20),16,18-triene-14-butanamide, N-butyl-γ-hydroxy-α,11-dimethyl-12-oxo-, 9,9-dioxide, (αR,γS,11S,14S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 824429-21-2 USPTAFULL

CN 2-Oxa-9-thia-12-azabicyclo[13.3.1]nonadeca-1(19),15,17-triene-13-butanamide, N-butyl-γ-hydroxy-α,10-dimethyl-11-oxo-, 9,9-dioxide, (αR,γS,10S,13S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 3 OF 3 USPTAFULL on STN (Continued)



RN 824429-29-0 USPTAFULL

CN 8-Thia-4-azabicyclo[13.3.1]nonadeca-1(19),15,17-triene-3-butanamide, N-butyl-γ-hydroxy-α,6-dimethyl-5-oxo-, 8,8-dioxide, (αR,γS,3S,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 824957-23-5 USPTAFULL

CN 2-Oxa-7,10-diazabicyclo[11.3.1]heptadeca-1(17),13,15-triene-11-butanamide, N-butyl-γ-hydroxy-α,8-dimethyl-6,9-dioxo-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 3 OF 3 USPTAFULL on STN (Continued)



RN 824429-23-4 USPTAFULL

CN 2-Oxa-7-thia-11-azabicyclo[12.3.1]octadeca-1(18),14,16-triene-12-butanamide, N-butyl-γ-hydroxy-α-methyl-10-oxo-, 7,7-dioxide, (αR,γS,12S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 824957-22-4 USPTAFULL

CN 2-Oxa-8,11-diazabicyclo[12.3.1]octadeca-1(18),14,16-triene-12-butanamide, N-butyl-γ-hydroxy-α,9-dimethyl-7,10-dioxo-, (9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/561,949

L12 ANSWER 3 OF 3 USPATFULL on STN (Continued)

10/561,949

=> d que stat

L10 STR



G1 C,O,N

Structure attributes must be viewed using STN Express query preparation.

L11 15 SEA FILE=REGISTRY SSS FUL L10

L12 3 SEA L11

=> d his full

(FILE 'HOME' ENTERED AT 13:10:49 ON 02 MAY 2007)

FILE 'REGISTRY' ENTERED AT 13:11:03 ON 02 MAY 2007

L1	STRUCTURE UPLOADED
	DIS
L2	0 SEA SSS SAM L1
L3	0 SEA SSS FUL L1
L4	STRUCTURE UPLOADED
	DIS
L5	0 SEA SSS FUL L4
L6	STRUCTURE UPLOADED
	DIS
L7	0 SEA SSS FUL L6
L8	STRUCTURE UPLOADED
	DIS
L9	0 SEA SSS FUL L8
L10	STRUCTURE UPLOADED
	DIS
L11	15 SEA SSS FUL L10

10/561,949

L12 FILE 'HCAPLUS, USPATFULL' ENTERED AT 13:17:56 ON 02 MAY 2007
3 SEA ABB=ON PLU=ON L11
D L12 1-3 IBIB ABS HITSTR
D QUE STAT

FILE HOME

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 1 MAY 2007 HIGHEST RN 934050-43-8
DICTIONARY FILE UPDATES: 1 MAY 2007 HIGHEST RN 934050-43-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

FILE HCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 May 2007 VOL 146 ISS 19
FILE LAST UPDATED: 1 May 2007 (20070501/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE USPATFULL

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 1 May 2007 (20070501/PD)
FILE LAST UPDATED: 1 May 2007 (20070501/ED)
HIGHEST GRANTED PATENT NUMBER: US7213269
HIGHEST APPLICATION PUBLICATION NUMBER: US2007094759
CA INDEXING IS CURRENT THROUGH 1 May 2007 (20070501/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 1 May 2007 (20070501/PD)

10/561,949

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2006
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2006

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	23.39	886.80
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.56	-1.56

STN INTERNATIONAL LOGOFF AT 13:19:45 ON 02 MAY 2007